To print: Select File and then Print from your browser's menu

Title: Lamotrigine And Topiramate Add-Ons Can Benefit Some Epilepsy Patients

URL: http://www.harcourt-international.com/jour
rnals/seiz/previous.cfm?art=seiz.2002.0681

Seizure 2002 Sep;11(6):356 "Long-term follow-up of topiramate and lamotrigine: a perspective on quality of life"
09/24/2002 05:34:13 PM
By Alison Palkhivala

About one-third of patients with refractory epilepsy will benefit over the long-term from add on therapy with lamotrigine or topiramate, according to the results of a five-year study. Stefan Kaiser and colleagues from the Raymond Way Neuropsychiatry Research Unit, Institute of Neurology, London, England conducted a prospective, long-term study of lamotrigine or topiramate as an add-on treatment in patients with refractory epilepsy. In this study, twenty patients with refractory epilepsy took lamotrigine and another 35 took topiramate in addition to whatever anticonvulsant medication they were already taking. After five years, seven of the 20 patients who started taking lamotrigine were still on the drug, and 13 of the 35 patients initially given topiramate were still taking it. Patients who remained on the study drugs experienced improvements in their seizure rates. Five of the seven patients taking lamotrigine and four of the 13 patients on topiramate were seizure free. Quality of life measurements revealed that patients taking the study drugs also benefited with respect to this parameter. According to the authors, approximately one-third of patients who are given lamotrigine or topiramate as add on therapies for refractory epilepsy will stay on the drug long-term. These patients will likely benefit from these therapies, both in terms of seizure control and quality of life.

http://www.harcourt-international.com/jour
rnals/seiz/previous.cfm?art=seiz.2002.0681

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.